Ticiana Leal, MD
Enriched profileProfessor, Department of Hematology and Medical Oncology; Director, Thoracic Medical Oncology Program; Medical Director, Clinical Trials Office; Leader, Lung Cancer Disease Team, Winship Cancer Institute · Emory University
Ticiana Leal is Professor, Department of Hematology and Medical Oncology; Director, Thoracic Medical Oncology Program; Medical Director, Clinical Trials Office; Leader, Lung Cancer Disease Team, Winship Cancer Institute at Emory University. OpenAlex indexes 190 publications with 9,534 citations (h-index 33); ClinicalTrials.gov lists 9 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 16 Oct 2026
Ticiana Leal, MD, is Professor, Department of Hematology and Medical Oncology at Emory University / Winship Cancer Institute of Emory University, Atlanta, GA. The public record shows 190 publications with 9,534 citations (h-index 33), centered on Lung Cancer (NSCLC/SCLC). It also documents an investigator role on 9 registered clinical trials, industry payments reported by 32 companies, 1 NIH-funded awards (2022–2025).
- Most recent indexed publication: 2026 · JCO oncology practice
- Top research focus: Lung Cancer (NSCLC/SCLC)
- 9 registered trials on ClinicalTrials.gov
- Open Payments reporting from 32 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 18 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 9 registered studies on ClinicalTrials.gov. The most recent:
- Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Sponsor: Nuvalent Inc.
Industry payments
Updated 16 Oct 2026
32 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Novocure Inc.Program year20258 payments$90,202openpaymentsdata.cms.gov ↗
- Amgen Inc.Program year20256 payments$39,374openpaymentsdata.cms.gov ↗
- JAZZ PHARMACEUTICALS INC.Program year202530 payments$38,973openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
25.4%Kinase inhibitor23.6%Tagrisso54%Alecensa11%Augtyro11%Gavreto9%Alunbrig8%Erlotinib Hcl8%Part D<11 patientsOther antineoplastic agents1.8%Krazati100%Part D<11 patientsNervous system
24.8%Phenothiazine10.5%Prochlorperazine Maleate100%Part D≥43 patientsGabapentinoids4.9%Gabapentin100%Part D≥12 patients+ 3 more classes in this area
Metabolism & gastrointestinal
22.7%Serotonin-3 Receptor Antagonist13.6%Ondansetron Hcl83%Ondansetron Odt17%Part D<11 patientsCorticosteroid4.8%Prednisone100%Part D≥11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 16 Oct 2026
1 NIH research award on record, funded 2022–2025 per NIH RePORTER. The latest:
- ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center
Emory University
FY2025$683,484UG1CA233259 - ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center
Emory University
FY2024$683,484UG1CA233259 - ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center
Emory University
FY2023$621,608UG1CA233259
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.
Journal of clinical oncology
Article2026 - Inhibition of hTERT/telomerase/telomere mediates therapeutic efficacy of osimertinib in EGFR mutant lung cancer.
The Journal of experimental medicine
Article2024
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/ticiana-leal-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - Other
winshipcancer.emory.edu/profiles/leal-ticiana.php
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗ - ResearchGate
researchgate.net/scientific-contributions/Ticiana-Leal-2314989684
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - X / Twitter
x.com/lealticiana
- LinkedIn
linkedin.com/in/ticiana-leal-134bb5131
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- LinkedIn
linkedin.com/posts/winship-cancer-institute_congrats-to-ticiana-leal-md-who-has-been-activity-7203817825935704065-sHUI
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - Other
onclive.com/view/variability-and-innovation-in-small-cell-lung-cancer-care-with-ticiana-leal-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.emoryhealthcare.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →iaslc.org ↗
- Associate Editor and Executive Editorial Board Member
The Journal of the National Comprehensive Cancer Network (JNCCN)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗ - Lung Cancer Section Editor
Current Treatment Options in Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗ - Editorial Advisory Board Member
Cancer (journal) and The Brazilian Journal of Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗ - Chair
NCI LUNG-MAP; Representative, ECOG-ACRIN
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗ - Vice-President/President-Elect
Georgia Society of Clinical Oncology (GASCO)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →gasco.us ↗ - Member: ASCO
AACR, ECOG-ACRIN, ESMO, Society for Immunotherapy of Cancer (SITC), International Association for the Study of Lung Cancer (IASLC)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗
Awards & honors
honors on the public record- Recognized with a Lifetime Achievement Award at the Illuminate 3.0 Oncology Town Hall
Mumbai, India (date not specified)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
Secondary affiliations
appointments beyond the home institution- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pub.orcid.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vjoncology.com ↗
- ASCO Post video: co-presented with Narjust Florez
MD, on metastatic NSCLC Tumor Treating Fields therapy
2023verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ajmc.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncdata.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Keith Delman, MD
Emory University
James Lah, MD
Emory University
John Puskas, MD
Emory University
Craig Hofmeister, MD
Emory University
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Julie Brahmer, MD
Johns Hopkins University School of Medicine
Enriqueta Felip, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center